EN | UA
EN | UA

Help Support

Back

Effect of pegloticase on hepatic fibrosis in people with gout

Gout Gout
Gout Gout

The study aimed to investigate if the non-alcoholic fatty liver disease (NAFLD) course is affected by a reduction in levels of serum urate.

See All

Key take away

In pegloticase treated chronic refractory gout patients, a consistent decrease in serum urate substantially lowered the Fibrosis-4 scores, improved hepatic fibrosis, and thus indicated a plausible effect on the progression of NAFLD.

Background

The study aimed to investigate if the non-alcoholic fatty liver disease (NAFLD) course is affected by a reduction in levels of serum urate.

Method

In this retrospective data analysis, a comparison was done between people with persistent urate-lowering to <1 mg/dL in response to biweekly pegloticase (responders, n=36) with people who were given placebo (n=43). Utilizing the Fibrosis-4 index, NAFLD was evaluated. The groups were compared with the use of 2 sample Wilcoxon tests or regression analysis.

Result

At the baseline, the mean (standard deviation) Fibrosis-4 values were 1.40 (0.86) in pegloticase responders and 1.04 (0.53) in people getting placebo. Over 6 months, a change of 0.26 (0.41) in Fibrosis-4 score was observed in patients receiving placebo. In pegloticase responders, a change of 0.13 (0.62) was seen. A profound difference in the change in the Fibrosis-4 values between pegloticase responders and placebo was noted (-0.15 [0.67] vs. 0.7 [0.42]) when only people with a Fibrosis-4 value >1.3 were taken into consideration (n=27).

The correlation between the serum urate area under the curve (AUC) over the 6-month trial period and the change in Fibrosis-4  value was R=0.33. Multivariable analysis demonstrated that serum urate AUC was the only considerable contributor to the alteration in Fibrosis-4  values.

Conclusion

Hence, the persistent decrease in serum urate indicates a plausible effect on the progression of NAFLD.

Source:

Clinical and Experimental Rheumatology

Article:

Improvement in hepatic fibrosis estimated by Fibrosis-4 index in pegloticase treated chronic refractory gout patients

Authors:

Naomi Schlesinger et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: